Latest filing published 18 Dec 2017 for PROVECTUS BIOPHARMACEUTICALS, INC., €5,288.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -9.4%Entry US$0.06 · Close at T+365 US$0.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John R. Glass: trading record in brief
John R. Glass appears in our data through filings on Provectus Biopharmaceuticals, Inc. shares, published by SEC (Form 4). We count 2 filings, every one of them for a trade on 14 December 2017.
No open-market sale appears; the market trades are 2 purchases worth €9,118. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
On 18 December 2017 came the latest disclosure, an open-market purchase for €5,288 in Provectus Biopharmaceuticals, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to John R. Glass
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 115,900 shares@ US$0.05458.0% of flowCommon StockSEC:0000899243-17-028955:1Canonical exit: 14 Mar 2018 (T+90)
- 84,100 shares@ US$0.053942.0% of flowCommon StockSEC:0000899243-17-028955:0Canonical exit: 14 Mar 2018 (T+90)
2 of 2 declarations